OncoProg
Prognostic risk stratification for colorectal cancer relapse
ApprovedActive
Key Facts
Indication
Prognostic risk stratification for colorectal cancer relapse
Phase
Approved
Status
Active
Company
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers is a private, commercial-stage diagnostics company leveraging biomarker and AI technology to personalize cancer care, starting with colorectal cancer. Its lead commercial product, ToxNav®, predicts patient risk of severe toxicity from common chemotherapies (5-FU/capecitabine), while its prognostic test, OncoProg, uses AI and digital pathology to stratify relapse risk. Founded by academic oncologists, the company is expanding through U.S. and European partnerships and has a pipeline aimed at broadening its technology to other cancers.
View full company profile